Company profile

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions and focus on single-use technologies are supporting biopharma companies around the world to develop and produce drugs safely, timely and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech employs more than 11,900 people in more than 25 countries.

Key Figures

in millions of € unless otherwise specified

<table>
<thead>
<tr>
<th></th>
<th>H1 2022</th>
<th>Δ in %</th>
<th>H1 2021</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue (Δ in const. fx)</td>
<td>1,724.3</td>
<td>+22.1</td>
<td>1,351.9</td>
<td>2,887.0</td>
<td>1,910.1</td>
</tr>
<tr>
<td>Order intake (Δ in const. fx)</td>
<td>1,826.7</td>
<td>-7.3</td>
<td>1,889.9</td>
<td>3,664.4</td>
<td>2,381.0</td>
</tr>
<tr>
<td>Underlying EBITDA²</td>
<td>607.0</td>
<td>+24.5</td>
<td>487.4</td>
<td>1,033.4</td>
<td>604.7</td>
</tr>
<tr>
<td>Underlying EBITDA² as % of sales revenue</td>
<td>35.2</td>
<td>-0.9pp</td>
<td>36.1</td>
<td>35.8</td>
<td>31.7</td>
</tr>
<tr>
<td>Underlying net profit after non-controlling interest³</td>
<td>405.2</td>
<td>+26.0</td>
<td>321.6</td>
<td>687.8</td>
<td>383.8</td>
</tr>
<tr>
<td>Earnings per share³ in €</td>
<td>4.40</td>
<td>+26.0</td>
<td>3.49</td>
<td>7.46</td>
<td>4.16</td>
</tr>
<tr>
<td>Equity ratio in %</td>
<td>48.6</td>
<td>+4.7pp</td>
<td>43.9</td>
<td>43.9</td>
<td>51.1</td>
</tr>
<tr>
<td>Ratio net debt to underlying EBITDA⁴</td>
<td>0.5</td>
<td></td>
<td>0.4</td>
<td>0.4</td>
<td>0.8</td>
</tr>
</tbody>
</table>

1 Figures were restated due to the finalization of the purchase price allocation for the acquisition of BIA Separations 2 Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items 3 Underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items, amortization and based on a normalized financial result and normalized tax rate 4 EBITDA including the underlying pro forma amount contributed by acquisitions for this period

Investment Highlights

1. Clear focus on the attractive biopharma sector
2. Long-term growth drivers and significant market entrance barriers
3. Market leading position in key technologies and recognized brand
4. High share of recurring revenue as well as diversified earnings base
5. Proven track record with alliances and acquisitions; strong presence in growth regions

Sales and Earnings Development

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue</td>
<td>1,051.6</td>
<td>1,081.0</td>
<td>1,212.2</td>
<td>1,440.6</td>
<td>1,910.1</td>
<td>2,887.0</td>
</tr>
<tr>
<td>Underlying EBITDA margin in %</td>
<td>27.5</td>
<td>27.3</td>
<td>28.2</td>
<td>29.3</td>
<td>31.7</td>
<td>35.8</td>
</tr>
</tbody>
</table>

Sales Revenue by Region 2021

- Americas: 33%
- EMEA: 41%
- Asia | Pacific: 26%

EMEA = Europe | Middle East | Africa

Earnings per Share¹ in €

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2021</td>
<td>1.92</td>
<td>1.96</td>
<td>2.38</td>
<td>2.85</td>
<td>4.16</td>
<td>7.46</td>
</tr>
</tbody>
</table>

2022 Guidance

<table>
<thead>
<tr>
<th></th>
<th>FY 2021</th>
<th>FY 2022¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue growth</td>
<td>51.1%¹</td>
<td>~15-19%</td>
</tr>
<tr>
<td>Underlying EBITDA margin</td>
<td>35.8%</td>
<td>&gt;35%</td>
</tr>
<tr>
<td>Capex Ratio</td>
<td>11.2%</td>
<td>~14.5%</td>
</tr>
</tbody>
</table>

¹ Underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate; rounded values

1 In constant currencies
**Strategy**

- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers’ production processes
- Global leading positions in key technology platforms; e.g., process filtration, fluid management, fermentation and membrane chromatography
- One of the widest portfolios in the industry with a clear focus on single-use technologies such as filters, bags and cell culture media
- Regionally focused on gaining market share in North America and leveraging our strong market growth in Asia
- Continuous expansion through complementary acquisitions and alliances

---

**Facts about the Share**

Ticker symbol: DIM
Ticker symbol Bloomberg: DIM:FP
Ticker symbol Reuters: STDM.P
ISIN: FR0013154002
Liquidity provider: Gilbert Dupont
Stock exchange: Euronext Paris
Market segment: Local Securities - Compartement A (Large Caps)
Indexes:
- SBF 120
- CAC Next 20
- CAC Large 60
- CAC HEALTH CARE
- STOXX Europe 600
- MSCI France

**Sartorius Stedim Biotech Share (indexed)**

July 1, 2021, to June 30, 2022

<table>
<thead>
<tr>
<th>200%</th>
<th>150%</th>
<th>100%</th>
<th>50%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Shareholder Structure**

December 31, 2021

- Sartorius AG ~74%
  - ~85% of voting rights
- Free float ~26%
  - ~15% of voting rights

**Financial Calendar**

October 19, 2022
Publication of Quarterly Statement Jan.-Sept. 2022

---

**Disclaimer**

This fact sheet contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.

---

**Contact**

Petra Kirchhoff  
Head of Corporate Communications  
Tel.: +49.551.308.1686  
Email: petra.kirchhoff@sartorius.com

Petra Müller  
Head of Investor Relations  
Tel.: +49.551.308.6035  
Email: petra.mueller2@sartorius.com